ZA201304139B - Combination - Google Patents

Combination

Info

Publication number
ZA201304139B
ZA201304139B ZA2013/04139A ZA201304139A ZA201304139B ZA 201304139 B ZA201304139 B ZA 201304139B ZA 2013/04139 A ZA2013/04139 A ZA 2013/04139A ZA 201304139 A ZA201304139 A ZA 201304139A ZA 201304139 B ZA201304139 B ZA 201304139B
Authority
ZA
South Africa
Prior art keywords
combination
Prior art date
Application number
ZA2013/04139A
Other languages
English (en)
Inventor
Rakesh Kumar
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of ZA201304139B publication Critical patent/ZA201304139B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2013/04139A 2011-01-11 2013-06-06 Combination ZA201304139B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161431508P 2011-01-11 2011-01-11
PCT/US2012/020863 WO2012097021A1 (en) 2011-01-11 2012-01-11 Combination

Publications (1)

Publication Number Publication Date
ZA201304139B true ZA201304139B (en) 2014-02-26

Family

ID=46507420

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/04139A ZA201304139B (en) 2011-01-11 2013-06-06 Combination

Country Status (15)

Country Link
US (6) US20130288984A1 (enExample)
EP (1) EP2663189B1 (enExample)
JP (1) JP6100700B2 (enExample)
KR (1) KR20140053836A (enExample)
CN (1) CN103298345B (enExample)
AU (1) AU2012205601B2 (enExample)
BR (1) BR112013017722A2 (enExample)
CA (1) CA2824201A1 (enExample)
EA (1) EA029000B1 (enExample)
ES (1) ES2689760T3 (enExample)
IL (1) IL227097B (enExample)
MX (1) MX356704B (enExample)
SG (2) SG10201600077RA (enExample)
WO (1) WO2012097021A1 (enExample)
ZA (1) ZA201304139B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016004267A (es) * 2013-10-01 2016-07-08 Novartis Ag Combinacion.
CA2929715A1 (en) * 2013-11-07 2015-05-14 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie2 kinase useful in the treatment of cancer
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
EA202091763A1 (ru) 2018-01-31 2020-12-14 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Комбинированная терапия для лечения мастоцитоза
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
JP7818502B2 (ja) 2019-08-12 2026-02-20 デシフェラ・ファーマシューティカルズ,エルエルシー 胃腸間質腫瘍を治療するためのリプレチニブ
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
SI4084778T1 (sl) 2019-12-30 2024-01-31 Deciphera Pharmaceuticals, Llc Formulacije inhibitorja amorfne kinaze in načini njihove uporabe
AU2020417282B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6328590B1 (en) 2000-07-20 2001-12-11 Emc Corporation Methods and apparatus for controlling attachment of an electronic module with a circuit board connector
ES2551293T3 (es) * 2004-03-24 2015-11-17 Abbvie Inc. Inhibidores de quinasas de pirazol tricíclicos
WO2006040649A1 (en) 2004-10-13 2006-04-20 Pharmacia & Upjohn Company Llc Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
JP2009506069A (ja) * 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
EP1840114A1 (en) 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
EP2004165A2 (en) 2006-04-05 2008-12-24 Novartis Pharma AG Synergistic combinations of anticancer agents for treating cancer
WO2007122686A1 (ja) 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
HRP20130961T1 (hr) 2006-08-25 2013-11-22 Janssen Oncology, Inc. Kombinacije za tretman raka
JP4299327B2 (ja) 2006-08-31 2009-07-22 トヨタ自動車株式会社 可変バルブタイミング装置
US8828451B2 (en) 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
US8357695B2 (en) 2006-10-13 2013-01-22 Basf Se Hydrates of 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)-pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
AU2008309383B2 (en) 2007-10-11 2012-04-19 Astrazeneca Ab Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
DE102008044901A1 (de) 2008-08-29 2010-03-04 Siemens Aktiengesellschaft Verfahren und Vorrichtung zur Auswahl eines Bestrahlungsplans sowie Bestrahlungsanlage
MY161598A (en) 2009-01-30 2017-04-28 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
UY32730A (es) 2009-06-26 2011-01-31 Novartis Ag Inhibidores de cyp17
WO2011044415A1 (en) 2009-10-08 2011-04-14 Glaxosmithkline Llc Combination
CN103841975A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt抑制剂化合物和厄洛替尼的组合以及使用方法
AU2012250650A1 (en) 2011-05-03 2013-11-14 University Of Rochester Methods for treating prostate cancer
BR112014000653A2 (pt) 2011-07-13 2017-02-14 Pharmacyclics Inc inibidores de tirosina quinase de bruton
WO2013053691A1 (en) 2011-10-10 2013-04-18 Zach System Process for preparing 17-substituted steroids
CA2856646C (en) 2011-11-30 2020-01-14 Astrazeneca Ab Combination treatment of cancer
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
US20160235714A1 (en) 2013-10-01 2016-08-18 Novartis Ag Enzalutamide in combination with afuresertib for the treatment of cancer

Also Published As

Publication number Publication date
CN103298345A (zh) 2013-09-11
JP6100700B2 (ja) 2017-03-22
US20150119337A1 (en) 2015-04-30
US20160375086A1 (en) 2016-12-29
ES2689760T3 (es) 2018-11-15
EP2663189B1 (en) 2018-07-04
AU2012205601B2 (en) 2016-03-24
US10449226B2 (en) 2019-10-22
SG191724A1 (en) 2013-08-30
US20120258933A1 (en) 2012-10-11
IL227097B (en) 2018-02-28
MX2013008074A (es) 2013-08-09
CA2824201A1 (en) 2012-07-19
EA029000B1 (ru) 2018-01-31
AU2012205601A1 (en) 2013-08-01
SG10201600077RA (en) 2016-02-26
CN103298345B (zh) 2016-12-14
MX356704B (es) 2018-06-11
EP2663189A4 (en) 2014-06-11
EP2663189A1 (en) 2013-11-20
US20160022641A1 (en) 2016-01-28
BR112013017722A2 (pt) 2016-07-12
US20170100449A1 (en) 2017-04-13
WO2012097021A1 (en) 2012-07-19
KR20140053836A (ko) 2014-05-08
EA201391027A1 (ru) 2014-01-30
JP2014507412A (ja) 2014-03-27
US20130288984A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
DK2691417T4 (en) Antistof fc-varianter
EP2723631A4 (en) QUADFOILER
EP2776444A4 (en) dihydropteridinones
ZA201304139B (en) Combination
PL2606715T3 (pl) Kombinacja prasująco-owijająca
DK2770906T3 (en) Applanationstonometer
AU5026P (en) Goldstrike Agapanthus inapertus
GB201121105D0 (en) Combination
GB201117693D0 (en) Combination
GB201116007D0 (en) Combination
GB201106339D0 (en) Combination
GB201114484D0 (en) Fedorak-a-lope
GB201112451D0 (en) Vent - a - car
GB201104240D0 (en) Quantocosmocrypt
GB201103804D0 (en) T-zee spotdrive
GB201102667D0 (en) Coolbreeze
GB201102443D0 (en) Atompower
GB201101772D0 (en) Hat-Pack
GB201100308D0 (en) CrossPic
GB201115772D0 (en) Ecoskim
GB201115387D0 (en) Schoolscene
GB201114957D0 (en) Papercut
GB201114842D0 (en) Beachm8
GB201104857D0 (en) Floodstop
GB201113677D0 (en) eMeetMe